NCT07320586 2026-03-13
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Shandong Tumor Hospital
Phase 2 Recruiting
Clinical Trials
167 trialsNCT07078604 2026-03-12
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT04253964 2026-03-06
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Wake Forest University Health Sciences
Phase 2 Recruiting
NCT05753306 2026-02-25
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Mayo Clinic
Phase 2 Recruiting
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04892953 2026-02-19
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT02530489 2026-02-17
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04115163 2026-02-11
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04781088 2026-02-11
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07392346 2026-02-11
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer
Chinese PLA General Hospital
Phase 2 Recruiting
NCT04862650 2026-02-10
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT07340398 2026-01-21
TAYLOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT05026905 2026-01-20
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Active not recruiting
NCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT04872985 2026-01-06
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT07139951 2025-12-31
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for the Treatment of Patients With Gastric and Gastroesophageal Junction Adenocarcinoma at High Risk of Peritoneal Recurrence
Mayo Clinic
Phase 2 Enrolling by invitation
NCT02905591 2025-12-26
XACT-LUNG
University of Iowa
Phase 2 Active not recruiting
NCT07226856 2025-12-22
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Mayo Clinic
Phase 2 Recruiting
NCT00494182 2025-12-17
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03910387 2025-12-16
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Emory University
Phase 2 Completed
NCT06492759 2025-12-16
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Not yet recruiting
NCT02654119 2025-12-12
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
Phase 2 Completed
NCT03132532 2025-11-25
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic
Phase 2 Completed
NCT04054362 2025-11-21
PINBALL
Barts & The London NHS Trust
Phase 2 Completed
NCT01750073 2025-11-18
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT02593175 2025-11-06
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04329065 2025-11-06
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
Phase 2 Recruiting
NCT06576115 2025-11-05
Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Recruiting
NCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT07016399 2025-10-30
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
Vanderbilt-Ingram Cancer Center
Phase 2 Recruiting
NCT02876107 2025-10-10
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04481204 2025-10-09
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04940286 2025-10-08
Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04216472 2025-09-30
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04929392 2025-09-04
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07136519 2025-08-22
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
Affiliated Hospital of Guangdong Medical University
Phase 2 Not yet recruiting
NCT03579771 2025-08-15
Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
Emory University
Phase 2 Completed
NCT04669197 2025-08-15
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
HonorHealth Research Institute
Phase 2 Active not recruiting
NCT07121595 2025-08-13
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT05624918 2025-07-31
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT06423326 2025-07-30
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Emory University
Phase 2 Recruiting
NCT05821556 2025-07-29
Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients
National Cancer Institute, Naples
Phase 2 Recruiting
NCT01463072 2025-07-28
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT02723331 2025-07-01
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
University of Colorado, Denver
Phase 2 Completed
NCT05451043 2025-06-26
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT00609791 2025-06-19
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04543071 2025-06-19
Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma
Columbia University
Phase 2 Recruiting
NCT04055649 2025-06-18
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Recruiting